Orphazyme A/S: Election of new members of the Board of Directors
November 16, 2017 00:16 ET
|
Orphazyme ApS
Company announcement Orphazyme A/S No. 4/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 16 November 2017 On 16...
Early close of offering of shares in Orphazyme
November 14, 2017 02:31 ET
|
Orphazyme ApS
Company announcement Orphazyme A/S No. 3/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 14 November 2017 NOT FOR...
ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA
November 07, 2017 09:13 ET
|
Orphazyme ApS
Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 7 November 2017 Orphazyme A/S ("Orphazyme" or the "Company"), a Danish biotech company...
Orphazyme publishes offering circular and the indicative offer price range for its IPO
November 06, 2017 02:38 ET
|
Orphazyme ApS
Company announcement Orphazyme A/S No. 2/2017 Ole Maaløes Vej 3DK-2200 Copenhagen Nwww.orphazyme.comCompany Registration No. 32266355 6 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR...
Orphazyme announces intention to launch an Initial Public Offering
October 24, 2017 02:20 ET
|
Orphazyme ApS
Company announcement Orphazyme A/S No. 1/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 24 October 2017 NOT...
ORPHAZYME COMPLETES ENROLMENT OF PATIENTS FOR PHASE 3 CLINICAL TRIAL IN NIEMANN-PICK TYPE C DISEASE
May 11, 2017 08:28 ET
|
Orphazyme ApS
Copenhagen, 11 May 2017 Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, today announced the completion of enrolment for its...
ORPHAZYME COMPLETES ENROLMENT OF PATIENTS FOR PHASE 3 CLINICAL TRIAL IN NIEMANN-PICK TYPE C DISEASE
May 11, 2017 08:07 ET
|
Orphazyme ApS
Copenhagen, 11 May 2017 Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, today announced the completion of enrolment for its lead...